New drug duo shows promise for Tough-to-Treat ovarian cancer
NCT ID NCT04502602
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-stage study tests two drugs, niraparib and neratinib, together in people with advanced solid tumors or ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find the safest dose and see if the combination can stop the cancer from growing for at least 4 months. About 18 adults are taking part in this research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.